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Abstract
Background: The therapy response of osseous metastases (OM) is commonly monitored by bone scintigraphies (BS).
The aim of this study was to compare visual evaluation of changes in tracer uptake with quantitation in absolute units
in OMs; 52 OMs from 19 patients who underwent BS with SPECT/CT at time points one and two (TP1/2) were analyzed
retrospectively, with an average of 10.3 months between TP1 and 2. Tracer uptake in lesions was visually compared by
two independent readers in both planar scintigraphies and SPECT/CT across both TPs and classified as regressive,
stable, or progressive. Quantitative analysis was performed by measuring peak standardized uptake values (SUV). Based
on quantitation, lesions were similarly classified as regressive (>30 % decrease), progressive (>30 % increase), or stable
(rest). If available, uptake in reference regions in the lower thoracic or lumbar spine was used for normalization.
Results: In OMs at TP1 and TP2, mean SUVpeak (±SD) was found to be 20.4 (±20.8) and 16.4 (±11.5), respectively. For
the reference region, mean SUVmean was 5.6 (±1.9) and 4.9 (±2.2). Agreement between quantitative and visual
assessment was only moderate, with an average Cohen’s kappa of 0.42 for planar scintigraphy and 0.62 for SPECT/CT.
Discrepancies occurred in between 11 and 22 of the 52 lesions, depending on the reader and whether planar or SPECT
imaging was considered.
Conclusions: Compared to measuring uptake in absolute units, visual evaluation of skeletal scintigraphies for change
in tumor metabolism yields inconsistent results in roughly one third of the cases.
Keywords: Bone scintigraphy, SPECT/CT, Absolute quantification, SUV
Background
Due to its high sensitivity, bone scintigraphy is part of
the standard diagnostic workup in common cancer
diseases such as prostate and breast cancer [1–4].
Commonly, regression or progression of bone metasta-
ses under therapy is determined by the decrease or
increase, respectively, in the occurrence of lesions in
consecutive bone scintigraphies. This is routinely per-
formed by visual interpretation.
However, visual interpretation of planar scintigraphy
and single photon emission computed tomography
(SPECT)(/CT) is a subjective exercise and highly user-
dependent. A standardized, semi-quantitative, more
user-independent evaluation has not yet been established
for the clinical routine.
Unfortunately, data on techniques for long-term bone
scan evaluation and correlation with clinical disease
progression is scarce, remaining a domain of magnetic
resonance imaging (MRI) [5], where the size of lesions
can be reliably tracked. Alternatively, positron emission
tomography (PET)/CT is applied [6–8], where the direct
measurement of tumor glycolysis and the ability to esti-
mate standardized uptake values (SUV) allows an
objective comparison of consecutive acquisitions [7, 9].
The superiority of combined SPECT/CT over con-
ventional SPECT and planar scintigraphy in bone
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scans has been shown in various studies [10–12].
Modern iterative SPECT/CT reconstruction methods
also allow for quantitative estimation of local tracer
uptake in specified volumes in absolute units of kilo-
Becquerel per milliliter. They employ corrections for
photon attenuation via data retrieved from CT, as well
as for photon scatter and the point spread function
[13–15], among other factors. Following system cali-
bration and normalization for body weight/surface and
injected dose, the calculation of SUVs in reconstructed
SPECT/CT images from patient studies is feasible
with an acceptable error [16]. Quantitative measure-
ments carry the potential to overcome the disadvan-
tages of a purely visual analysis. Reading conventional
gamma camera images generally has two sources of
variance. The first of these is the reproducibility of
placement of the volume of interest (VOI) to be evalu-
ated, and the second is the actual assessment of the
local amount of tracer uptake. While not alleviating
the need for manual VOI placement, quantitative
measurements replace the potentially subjective deter-
mination of uptake in the VOI, thus minimizing the
latter cause of variance, leading to increased intra-
and inter-reader reproducibility.
The aim of this study was to assess the agreement
between visual and quantitative evaluation of changes in




Our analysis was approved by the local ethics commis-
sion of the university Erlangen-Nuremberg medical
faculty (application number 4053). Due to the retro-
spective nature of the analysis, written consent from
the patients was not necessary. From our clinical data-
base, we retrieved image datasets from patients with
osseous metastases due to breast or prostate cancer
who had undergone two planar bone scintigraphies
and standard SPECT/CT studies between January 2012
and October 2014.
Selection criteria were the following:
 Referral of patient for staging of malignant disease
by skeletal scintigraphy
 At least two SPECT/CT examinations with
overlapping field of view (FOV)
 At least one osseous metastasis in SPECT/CT FOV
with clear-cut and typical SPECT and CT
abnormality
 Absence of any kind of metal or surgical implants in
the FOV
 Access to measured prepared activity, time of
measurement, injection time, residual syringe
activity, time of residual syringe activity
measurement, and patient weight
Overall, 19 patients conformed to the above criteria.
As part of palliative therapy, 8 of 19 patients received
bisphosphonates between both scans. The demographic
and clinical data of these subjects are provided in Table 1;
16 patients were females suffering from metastatic breast
cancer, while 3 were male with metastatic prostate
cancer.
Data acquisition and reconstruction
In vivo patient imaging was acquired at our institution
on either a Symbia T6 or a Symbia T2 (Siemens Molecu-
lar Imaging, Hoffman Estates, IL, USA). SPECT scans
were carried out using low-energy high-resolution
(LEHR) collimation, 256 by 256 matrix size, and a total
of 120 projections (60 stops) over 360° with a dwell time
of 15 s per stop. Following the SPECT acquisition, a
low-dose CT scan was performed with 130 kV and 30
reference mAs using adaptive dose modulation (CARE
Dose 4D). The CT data were generated with 5 and
3 mm slice thicknesses using smooth, medium, and
sharp kernels (B08s, B41s, and B70s, respectively). The
B08s kernel was solely used for SPECT attenuation
correction.
In the study cohort, the injected activity was 8.0 ±
1.1 MBq (6.5 to 10.1 MBq) of 99mTc-diphosphono-pro-
panedicarboxylic acid (99mTc-DPD) per kilogram of body
weight for time point 1 and 7.6 ± 0.6 MBq (6.3 to
8.5 MBq) for time point 2, respectively (TP1/TP2). The
mean total activity administered was 573.2 ± 105.4 MBq
(330–750 MBq) and 542 ± 80.4 MBq (409–699 MBq), re-
spectively. The slightly lower injected activity at TP 2
mainly reflects newer regulations on radioactive drugs in
German law, as recommended by the “Bundesamt für
Strahlenschutz”. The SPECT/CT scan was performed on
average 231 ± 57 min (146–343 min) and 234 ± 37 min
(186–303 min) after intravenous injection. The injected
dose and time lapse between injection and acquisition
for each subject, as well as patient weight, can be found
in Table 2. The mean elapsed time between TP1 and
TP2 was 10.3 ± 5 months, ranging from 3 to 24 months
(see Table 1).
SPECT reconstruction was performed using Flash3D
[13, 15, 16], an ordered subset expectation maximization
(OSEM) reconstruction algorithm with depth-dependant
3D (axial and trans-axial) resolution recovery, scatter
correction, and attenuation correction based on attenu-
ation maps derived from the B08s CT data. Camera cali-
bration and OSEM SPECT reconstruction parameters
(four subsets, eight iterations, no post-smoothing) used
for quantitative evaluations were carried out according
to a previously published protocol [16].
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Data analysis
Both qualitative and quantitative image analyses were
performed. Qualitative analyses were carried out on
workstations using the Oncology and MM Basic tool of
the Syngo.via software (Siemens Molecular Imaging,
Hoffman Estates, IL, USA).
Qualitative evaluation
In the first step, the planar scintigrams and the SPECT/
CT datasets from TP1 and TP2 were displayed and eval-
uated for metastatic lesions contained in a common
FOV. As we generally acquired only one SPECT bed
position, the FOV evaluated in this study was thus usu-
ally limited by that of the SPECT/CT. Of the lesions
found, a maximum of six metastases detectable on both
SPECT/CT scans of the patient in question were se-
lected for visual and quantitative analysis. The selection
criterion was a visually definable increase of uptake, with
more focal metastases preferable. In total, 52 lesions
from 19 patients were included. This process was per-
formed by reader one only.
In the next step, the TP1 and TP2 image datasets were
jointly displayed, and the uptake in the marker lesions
was visually compared and classified as increased, de-
creased, or equal in uptake.
This analysis was performed independently from each
other by two physicians for both planar scintigraphy and
SPECT/CT. Reader 1 had 4 years’ experience in clinical
Table 2 Injected dose at time point 1 and 2 and time lapse















P001 95 656 699 290 186
P002 65 583 500 249 248
P003 67 523 548 343 203
P004 88 625 614 237 292
P005 110 750 693 232 230
P006 62 463 468 301 228
P007 76 699 566 146 220
P008 71 515 587 290 280
P009 60 443 521 296 187
P010 60 608 499 252 234
P011 60 584 420 192 278
P012 65 614 475 163 287
P013 48 330 409 179 222
P014 90 708 620 172 211
P015 74 625 493 256 206
P016 66 450 534 252 303
P017 70 589 562 168 191
P108 76 493 493 173 218
P019 76 633 597 206 221
Table 1 Clinical data of all subjects included in the analysis
Subject Type of cancer Age Time between scans (months) Therapy between scans Bisphosphonates
P001 Prostate 77 6 Leuprorelin/bicalutamide None
P002 Breast 50 11 Tamoxifen Zolendronate
P003 Breast 62 6 Tamoxifen Zolendronate
P004 Breast 57 11 Denusomab/everolimus none
P005 Breast 54 24 Tamoxifen Zolendronate
P006 Breast 59 12 Fulvestrant Zolendronate
P007 Breast 48 6 Denusomab None
P008 Breast 71 6 Anastrazole Zolendronate
P009 Breast 73 11 Exemastane/everolimus None
P010 Breast 66 12 None Zolendronate
P011 Breast 71 4 Denusomab/letrozole None
P012 Breast 57 13 Anastrazole None
P013 Breast 44 7 Letrozole Zolendronate
P014 Prostate 75 15 Abiraterone/goserelin/docetaxelce Zolendronate
P015 Breast 74 3 Denusomab/afinitor/exemstan None
P016 Breast 42 12 Eribulin None
P017 Breast 49 12 Letrozole None
P018 Breast 71 16 Denosumab/trastuzumab/letrozole None
P019 Prostate 78 14 Bicalutamide None
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nuclear medicine and 4 years’ experience in reading skel-
etal SPECT/CT. Reader 2 was board-certified with 28
years’ experience in clinical nuclear medicine and 9 years’
experience in reading skeletal SPECT/CT.
Quantitative evaluation
The delineation of the VOIs was performed using the
standard clinical volumetric analysis tool provided by
the camera’s vendor. The B70s CT data were used to
drive the VOI selection in a fused SPECT/CT display.
An ellipsoidal VOI was defined on the fused image rep-
resentation around each lesion in question, and peak
count values (average counts within a 1 cm3 sub-volume
of interest about the VOI maximum) were measured. In
the follow-up images, a VOI at an analogous anatomical
position and of a comparable volume was drawn. Due to
the manual fashion of the VOI definition, exact position
and size of the VOI are subject to intra- and inter-reader
variability.
When the lumbar or thoracic spine was included in the
FOV, the spongeous bone of one vertebral body unaffected
by SPECT or CT pathology both on the first and on the
follow-up scan was selected as reference tissue. The mean
count values of the reference tissues were measured by
manually drawing VOIs in the inside of the vertebral body
such that the borders coincided with the vertebral cortical
bone shell, as reported previously [17]. Reference regions
were available in 17 of 19 patients only. In these patients, a
total of 46 lesions were available for quantitation. Of the
two patients lacking a reference region, one had only the
base of the skull included in the FOV, and the second
showed a multifocal bone involvement in all vertebral
bodies imaged with SPECT/CT.
Extracted count values of each VOI were converted
to absolute activity concentrations according to previ-
ously mentioned methods [16]. All data were decay-
corrected to time of injection in order to control for
fluctuations in start time of the acquisition. Final
values of quantitative tracer concentrations are thus
defined at injection time.
After determining the local tracer activity concentra-
tion in kiloBecquerel per milliliter, normalization by
injected activity (corrected for residual activity in the
syringe) and body weight yielded SUVs. Additionally, the
ratio between SUVpeak of the lesion and SUVmean of the
corresponding reference region was calculated to correct
for global fluctuations in bone metabolism.
Similar to the Response Evaluation Criteria in Solid
Tumors Version 1.1 (RECIST 1.1) criteria in CT and
suggested positron emisson tomography response cri-
teria in solid tumors version 1.0 (PERCIST criteria) in
FDG-PET, a change of more than 25 % in tracer uptake
was defined as significant [18–20]. The lesions were then
again classified as progressive (>30 % increase), regressive
(>30 % decrease), and stable (in between) [18–20]. This
classification was performed on basis of the absolute
quantification as well as the above described ratios.
Quantification of the target lesions and reference
regions in SPECT/CT was carried out independently by
the two readers.
Statistical analysis
Inter- and intra-observer, as well as inter-method agree-
ment were assessed using Cohen’s kappa, a statistical
metric useful for measuring inter-rater agreement [21].
Cohen’s kappa k is calculated on the basis of the ob-
served agreement p0 between two raters and the random
agreement pe expected for statistically independent deci-
sions of both raters: k ¼ p0pe1pe . Landis and Koch provide
guidance for interpreting values of k , which we conse-
quently adapted for our evaluation and are displayed in
Table 3 [22].
The variables were tested for differences using a
Mann-Whitney U test. Correlations were tested using a
two-sided Spearman’s rank correlation coefficient. Sig-
nificance was accepted at p < 0.05.
In the “Results” section, we report quantitative mea-
sures, including tracer activity concentration expressed
in SUV. The data are described by providing their mean
values and their standard deviations (SD). Statistical
analysis was performed using SPSS© Version 19 (IBM,
Copyright 2010, Armonk, New York, USA).
Results
Nineteen patients with a total of 52 bone lesions, charac-
terized by both CT and bone scintigraphy as osseous
metastases, were included in the quantitative analysis.
The location of the analyzed lesions is listed in Table 4.
A representative patient example is given in Fig. 1; 17
patients with in a total of 46 lesions were extracted for
estimation of uptake ratios.
Qualitative evaluation
The respective numbers of classified lesions of the two
readers using planar bone scintigraphies (BS) and SPECT/
CT can be found in Tables 5 and 6. Inter-observer
Table 3 Proposed scoring system of Landis and Koch
(Biometrics 1977 [22]) for rating of the Kappa statistic
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agreement of the visual analysis was k = 0.46 (p < 0.01) for
planar scintigraphy and k = 0.35 (p < 0.01) for SPECT/CT
(Table 7). The aggregated (both readers = 104 lesions)
inter-method agreement between the visual analysis of
planar scintigraphy and SPECT/CT was k = 0.36 (p < 0.01)
(Table 8).
Quantitative evaluation
Across all lesions and both readers, average SUVpeak
(±SD) of the osseus metastases (OMs) was 20.4 (±20.8)
at TP1 and 16.4 (±11.5) at TP2. For the reference
regions, average SUVmean was 5.6 (±1.9) and 4.9 (±2.2)
at TP1 and TP2, respectively. Both SUV measurements
in lesions and background had a high correlation with
r = 0.99 (p < 0.01) and r = 0.92 (p < 0.01), and the resulting
Table 4 Location of OMs and corresponding mean peak
standard uptake values (SUVpeak) with standard deviation (SD)
Region Number Mean SUVpeak SD SUVpeak
Skull 2 17.1 9.5
Shoulder 3 11.1 7.7
Cervical spine 2 30.9 1.6
Thoracical spine 14 24.7 33.8
Lumbar spine 10 36.2 39.1
Pelvis 9 20.6 18.0
Ribs 12 19.5 13.3
Fig. 1 Planar bone scintigraphy and fused SPECT/CT at TP1 (a) and TP2 (b) of a patient with metastatic breast cancer. Both metastases in the
thoracic spine were visually considered stable. Quantitative assessment revealed an increased tracer uptake for the lesion in thoracic vertebra
body 9 (T9), whereas activity concentration of the lesion in thoracic vertebra body 6 (T6) was stable
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classification showed an almost perfect inter-observer
agreement with k = 0.94 (p < 0.01).
The ratio SUVpeak to SUVmean was found to be 3.8
(±3.3) and 4.1 (±2.7) for TP1 and TP2, respectively, the
resulting classification showed an inter-observer agree-
ment of k = 0.87 (p < 0.01) (Table 7). In 30.4 % of the
lesions, the classification assessed by uptake ratios was
different compared to classification according to quanti-
tative uptake alone (k = 0.55; p < 0.01) (Table 8).
Comparison of qualitative and quantitative evaluation
Discrepancies between visual and quantitative assess-
ment occurred in between 11 (21.1 %) and 22 (42.3 %)
of the 52 lesions, depending on the reader and whether
planar or SPECT/CT imaging was considered (Table 5).
The comparison of visual assessment and uptake-ratio
analysis yielded discrepant findings in the same frequency
(Table 6).
In Table 7, we report the according Kappa statistic for
the inter-observer agreement.
When aggregating the classification results for both
observers in order to compare inter-method agreement
between quantitative and visual assessment of planar
scintigraphy, k was 0.42 (p < 0.01). When comparing the
same quantitative results to visual assessment of the
SPECT/CT, k was 0.62 (p < 0.01). The results of the ag-
gregated comparison of visual and quantitative assess-
ment and the uptake ratios can be found in Table 8.
Discussion
To the best of our knowledge, this is one of the first
studies comparing visual and quantitative evaluation of
disease progress in bone scans while reporting DPD up-
take in healthy and diseased bone in absolute units and
capitalizing on recent methodological advances in
SPECT/CT (for a review, see Ritt et al. [14] and Bailey
et al. [23]).
Studies on the efficacy of bone scans for therapy mon-
itoring are scarce, but is has been shown that the results
of bone scans and fluorine PET heavily influence therapy
decisions in clinical practice: Hillner et al. investigated
the influence of 18F-fluoride PET/CT on therapy man-
agement in 2217 patients with osseous metastases. In
40 % of the cases, a change in tumor therapy based
solely on the results of the PET/CT was observed [7].
Despite the missing proof that progress as assessed by
bone scintigraphy is correct, Imbriaco et al. introduced a
method of measuring metastatic bone involvement in
bone scintigraphy of prostate cancer—the so-called bone
Table 5 Results from visual lesion classification compared to
those from assessment of peak standard uptake value (SUVpeak)
in 52 metastatic bone lesions





Reader 1 planar BS 15 21 16 18




Reader 2 planar BS 20 12 20 22
Reader 2 SPECT/CT 18 12 22 14
Lesions were classified either visually or based on the absolute peak tracer
uptake. In this case, a change of more than 30 % in peak tracer uptake was
rated as a significant increase (=progressive) or decrease (=regressive). All
other lesions were classified stable. The listed number of discrepant lesions
refers to the comparison of each visual analysis to the quantitative assessment
Table 6 Results from visual lesion classification compared to
those from assessment of uptake ratios in 46 metastatic bone
lesions
Progressive Stable Regressive Discrepant
lesions (n)
Reader 1 uptake ratios
SPECT/CT
12 20 14
Reader 1 planar BS 14 18 14 14
Reader 1 SPECT/CT 10 15 21 16
Reader 2 uptake ratios
SPECT/CT
10 22 14
Reader 2 planar BS 19 9 18 23
Reader 2 SPECT/CT 18 8 20 19
Lesions (OM) were classified either visually or based on ratios of absolute peak
tracer uptake in the OM divided by the mean tracer uptake in the reference
region. In this case, a change of more than 30 % in the ratio was rated as a
significant increase (=progressive) or decrease (=regressive). All other lesions
were classified stable. The listed number of discrepant lesions refers to the
comparison of each visual analysis to the quantitative assessment






Uptake Ratio SPECT/CT 0.87
Table 8 Inter-method comparison of aggregated results for
both readers (n = 2*52 = 104 lesions)
Kappa
Visual planar vs. visual SPECT/CT 0.36
Visual planar vs. quantitative SPECT/CT 0.42
Visual planar vs. uptake ratio SPECT/CT 0.40
Visual SPECT/CT vs. quantitative SPECT/CT 0.62
Visual SPECT/CT vs. uptake ratio SPECT/CT 0.44
Quantitative SPECT/CT vs. uptake ratio SPECT/CT 0.55
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scan index (BSI) [24]—and could show that it features a
high correlation with prostate-specific antigen (PSA) and
low intra- and inter-observer variability. The BSI is cal-
culated as the sum of the product of fractional bone
weight and the percentage of tumor involvement for
each bone in the body. However, primarily due to the
time-intensive assessment process, the bone scan index
has not become established in the clinical routine.
For other modalities, various semi-quantitative classifi-
cation systems of tumor response in bony lesions have
been previously researched.
In the late 1970s, the Union for International Cancer
Control (UICC) and the World Health Organization
(WHO) introduced a method in which criteria were
based on conventional X-ray and planar skeletal scintig-
raphy [19, 25–27]. Dependent on tumor size develop-
ment in X-ray imaging, lesions are classified as partially
responsive (at least 50 % decrease), progressive (more
than 25 % increase), and stable (in between). A dis-
appearance of all lesions in skeletal scintigraphy is rated
as complete remission.
The most commonly used MRI/CT tool for monitoring
therapy is provided by the RECIST, first published in 2000
[19] and revised in 2009 [18]. By measuring certain target
lesions, overall response is evaluated. Unfortunately, soli-
tary bone lesions are characterized as immeasurable under
this scheme, and only osteolytic lesions with involvement
of surrounding soft tissue can be included.
Quantitative uptake of osseous lesions
Average SUVmean in morphologically healthy spongeous
bone of the vertebra was 5.6 (±1.9) and 4.9 (±2.2) in our
subjects, thus agreeing closely with data published earl-
ier by our group for DPD uptake in the lower lumbar
spine [17]. Malignant osseous lesions had a considerably
higher uptake of 99mTc-DPD than normal osseous tissue,
with an average SUVpeak of 20.4 (±20.8) and 16.4 (±11.5)
for TP1 and TP2, respectively.
Interestingly, osseous DPD uptake determined by
SPECT was in the same range as that reported for 18F-
fluoride measured by PET. In a study by Uchida et al.,
who investigated the influence of alendronate on bone
metabolism in glucocorticoid-induced osteopenia, SUV-
mean values are given as 5.9 in the lumbar spine of a
bone-healthy control group [28]. Furthermore, Cook
et al. reported maximum SUVs for 18F-fluoride in bone
metastases from 11.4 to 98 (mean 37.2) in their group of
five subjects with castrate-resistant prostate cancer
undergoing a treatment with 223Ra-dichloride [29]. In
our data, SUVmax rated 36.7 (±39.5) and 24.5 (±18.0) for
TP1 and TP2, respectively.
The clinical impact of truly quantitative SPECT/CT
has as yet not been established and is also beyond the
scope of this current study, mainly due to our lack of a
gold standard. Expectations are that quantitative
workups could prove beneficial when diagnosing dis-
eases affecting tracer uptake in a diffuse rather than
focal manner such as osteoporosis [17] or three-vessel
coronary artery disease [30]. Other potential benefits in-
clude improved personalized dosimetry of radionuclide
therapies and further the use of SPECT/CT for monitor-
ing therapy, e.g., in neoplastic disease, analogously to
PET [23].
Comparison of qualitative and quantitative evaluation
Based on our small dataset, we could show a large dis-
crepancy between visual and quantitative analysis, yield-
ing inconsistent results in up to 42.3 % of the inspected
lesions. Furthermore, visual classification results from
both planar scans and SPECT/CT images had only a fair
to moderate inter-observer agreement with a k of 0.46
and 0.35, respectively. One possible interpretation of this
finding is that changes in tracer uptake between TP1
and TP2 were only minor, leading to differences in visual
interpretation of the same scan [31]. In comparison,
inter-observer agreement in quantitative evaluation was
almost perfect with a k of 0.94.
Using the classification based on the uptake ratios, dis-
crepancies to visual evaluation could be found in a com-
parable frequency, resulting in a correspondingly fair
agreement. Whether uptake ratios or a quantitative
evaluation are better suited for assessment of local tracer
uptake changes could not directly be evaluated in this
study, but agreement between both methods was sub-
stantial. However, inter-observer agreement using uptake
ratios was slightly inferior compared to quantitation.
This is most likely caused by the greater variability due
to differing SUVmean values between readers, which was
effectively magnified by the smaller magnitude of the re-
ported quantities when using uptake ratios.
Results on uptake-ratio analysis have been reported for
fluoride PET. In 2011, Cook et al. published a study on
therapy monitoring with 18F-fluoride-PET/CT in pa-
tients with castration-resistant prostate cancer treated
with 223Ra-dichloride [29]. Five patients receiving 2 cycles
of therapy 6 weeks apart underwent F-18-fluoride-PET/
CT scans at baseline as well as in weeks 6 and 12 after
institution of therapy. Although PSA showed a signifi-
cant change in all patients, the scans were visually rated
as unchanged. However, semi-quantitative analysis of
tracer uptake revealed an agreement of changes in bone
metabolism and the course of the PSA and serum alka-
line phosphatase (ALP) values. Thus, though also limited
in patient number, the authors could demonstrate the
superiority of uptake ratios over visual assessment [29].
Based on our results and those reported in literature,
there are strong indications that visual analysis of bone
scans for longitudinal changes in tracer uptake of
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individual lesions is unreliable and should be substituted
by semi-quantitative or quantitative evaluation.
Limitations
As mentioned before, predictions about the clinical im-
pact of such measurements cannot be made on the basis
of our data due to the missing gold standard and our
small patient number.
In particular, histological results are available only infre-
quently, and furthermore, tumor markers in certain tumor
entities like breast cancer, which represents the majority
of our study collective, are unreliable [32]. A further
confounding variable is the flare phenomenon, which is
caused by the temporary increase of reparative osteoplas-
tic activity in metastatic bone lesions after treatment and
occurs in prostate and breast cancer and can potentially
lead to false-positive results [33]. In patients with breast
cancer, this phenomenon was observed in up to 35 % of
the cases in an average of 3.3 ± 1.4 months after therapy
initiation. A stabilization of bone metabolism was seen
within 6.2 ± 3.0 months [34]. Since, on average, 10.3 ±
5 months elapsed between our two scans, the influence of
this phenomenon on our results should be only minor.
Conclusions
In this study, we compared agreement of the visual
evaluation of both planar scintigraphy and SPECT/CT
with the quantitation of local tracer uptake in longitu-
dinal bone scans of patients with osseus metastases.
Compared to measuring DPD uptake in absolute units,
visual evaluation of skeletal scintigraphies for change in
tumor metabolism yielded inconsistent results in up to
42 % of the cases. Furthermore, visual analysis showed
only moderate inter-observer agreement, while inter-
observer agreement in quantitative evaluation was al-
most perfect. This suggests that longitudinal analysis of
bone scans for changes in tracer uptake of individual le-
sions should be performed using quantitation of tracer
uptake rather than solely by visual assessment to ensure
that consistency in patient management is maximized.
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